UCB7853

UCB7853 is an investigational anti-alpha-synuclein monoclonal antibody developed for the potential treatment of Parkinson's disease. It acts by targeting and inhibiting the extracellular spread of pathological species of alpha-synuclein, a protein whose abnormal accumulation and misfolding are key neuropathological hallmarks in Parkinson’s disease. By binding to alpha-synuclein, UCB7853 aims to modify disease progression through passive immunotherapy. The drug is administered intravenously and has completed Phase 1 clinical trials evaluating its safety, tolerability, and pharmacokinetics in both healthy participants and individuals with Parkinson’s disease[1][2][3][4][5][6][7].